01.10.2014 | Editorial
Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2014
Einloggen, um Zugang zu erhaltenExcerpt
One should always be cautious of undertaking a rigorous examination of a subject lest hubris interferes with balance and the confidence of “experience” undermines the rigor of facts. Notwithstanding these caveats, this missive seeks to cast a critical light on what, to date, has proven to be a contentious subject: the utility of peptide receptor radionuclide therapy (PRRT) in the management strategy of neuroendocrine tumors (NETs). Mindful of the Einsteinian adage—“whoever undertakes to set himself up as a judge of Truth and Knowledge is shipwrecked by the laughter of the gods” [1]—we propose to provide a balanced assessment of the matter from the perspective of evaluators of the therapy as opposed to purveyors. …Anzeige